Biography for Eric Sagonowsky
Eric Sagonowsky, Associate Editor
Eric Sagonowsky is an associate editor with the FierceMarkets Life Sciences team. Before joining Fierce in November 2014, Eric worked as a news reporter for the Manistee News Advocate in Manistee, Mich., covering government and crime issues. Eric graduated from Ohio University's E.W. Scripps School of Journalism in 2012 with a degree in Online Journalism. On campus, Eric wrote for The Athens News and The New Political. In his free time, Eric enjoys outdoor recreation, following sports of all kinds and exploring the metro D.C. area. He can be reached at email@example.com. Follow @EricSFierce on Twitter.
Articles by Eric Sagonowsky
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.
Seqirus--the world's second largest flu vaccine player formed CSL's purchase of Novartis flu vaccines--this week said it's expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there.
Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.
Brazil officials signed off this week on funding for a late-stage dengue vaccine trial, adding another twist to the global dengue vaccine competition amid the launch of the first approved jab.
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine.
Merck, GlaxoSmithKline and public health officials in the United States have some big new numbers to tout to promote HPV vaccination. On Monday, a group of federal researchers said that since the introduction of Gardasil in 2006, HPV infection rates in teenage girls have fallen by nearly two-thirds.
A review of superbugs by the British government says that vaccines may play a role in combating the public health threat. More vaccinations would reduce infections, the report states, and in turn the need for widespread antibiotic use which promotes superbug development.
Sanofi is moving into 2016 with a head of steam for its Dengvaxia launch, with execs announcing on the company's year-end conference call that the French pharma has delivered its first million doses in the Philippines.
Zika developments continued at an accelerated pace this week with the WHO saying that India's Bharat Biotech and the U.S. National Institutes of Health are farthest along in vaccine development.